BIM and PUMA both contribute to the killing of lymphoid cells by glucocorticoids [92, 185] and BIM is also needed for the killing of malignant cells by inhibitors of oncogenic kinases, such as the BCR-ABL inhibitor Gleevec in chronic myeloid leukaemia (CML) [150, 151, 208]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.